Answers are grounded in this paper and cite their sources.
Roxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4 months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies.
No takes yet. Share an insight, caveat, or question.
Csiky et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: